ACNS1723: A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND# 145355)

Contact:

NCT Number:

Protocol:

AAAS7661

Study Status:

Active/Enrolling

Population:

Pediatrics

Phase:

II

The purpose of this study is to see if using two drugs called dabrafenib and trametinib after radiation treatment will be better than treatments used in the past in improving survival for patients with newly-diagnosed high grade glioma (HGG) that have the BRAF V600-mutation (a gene change within tumor cells). It is expected that the combination of these two medications that target the gene change and its cellular growth pathway will demonstrate clinical success when given as maintenance therapy following standard radiation therapy. Treatment on this study may last for approximately 2 years.

Are you Eligible? (Inclusion Criteria)

  • Patient must be between 3 and 21 years of age at the time of enrollment.
  • Patient must have a confirmed newly diagnosed high-grade glioma with BRAF V600 mutation.
  • Patients must have negative results for H3 K27M.
  • Patients must also meet all other eligibility criteria as outlined in the study protocol.

Specialty Area(s)

Brain and Spinal Tumors, Childhood and Adolescent Cancers (Pediatric), Precision Oncology

Principal Investigator

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032